OpGen and Merck will collaborate to develop rapid diagnostics and informatics tools for antibiotic resistance. Under the terms of the deal, Merck will give OpGen access to its library of 200,000 bacterial pathogens in order to support OpGen’s development of rapid DNA tests and a genomic database of antibiotic-resistant pathogens … more

Thermo Fisher Scientific has submitted a premarket approval application to the US Food and Drug Administration for a next-generation sequencing-based companion diagnostic. The firm submitted an application for its Oncomine Universal Dx test for non-small cell lung cancer that it developed in partnership with Novartis and Pfizer … more